Informal Request for ATI Records Previously Released

Organization: Health Canada

Year: 2023

Month: November

Request Number: A-2023-000149

Request Summary: The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal ingredient Enzalutamide; The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for Enzalutamide; The strength (s) and dosage form of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 having the medicinal ingredient Enzalutamide.; The Canadian Reference product used to support of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 having the medicinal ingredient Enzalutamide.; Any information pertaining to a Risk Management Plan (RMP) submitted to support of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 having the medicinal ingredient Enzalutamide.

Disposition: Disclosed in part

Number of pages: 77

Date modified: